Could an arthritis drug ease tough schizophrenia symptoms?

NCT ID NCT07615075

First seen Jun 08, 2026 · Last updated Jun 08, 2026

Summary

This study tests whether mirikizumab, a drug that blocks IL-23 (a protein involved in inflammation), can improve negative symptoms like lack of motivation and social withdrawal in people with schizophrenia. The trial enrolls 40 adults who have a specific immune marker (AGA IgG antibodies) linked to higher inflammation. Participants continue their usual antipsychotics and receive either mirikizumab or a placebo for 16 weeks to see if symptoms and thinking improve.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Maryland Psychiatric Research Center (MPRC) Outpatient Research Program (ORP); the MPRC Treatment Research Program (TRP)

    Catonsville, Maryland, 21228, United States

Conditions

Explore the condition pages connected to this study.